drugset / Trial / NCT00002889

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

NCT00002889 ↗

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Imaging procedures such as MRI may improve the ability to determine the response of prostate tumors to therapy. PURPOSE: Phase II trial to study MRI results in patients with prostate cancer that has been treated with radiation therapy plus androgen suppression therapy.

Timeline

Start
1997-05
Primary completion
2004-01
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Background Flutamide Small molecule — Oral
Background Goserelin Other / unclassified — Subcutaneous
Background Leuprolide Other / unclassified — Intramuscular

Indications